

**Wanbury Limited**

Regd. Office : BSEL Tech Park, B-wing
10th Floor, Sector-30 A,
Opp. Vashi Railway Station,
Vashi Navi Mumbai 400 703
Maharashtra, INDIA
Tel. : +91-22-6794 2222
+91-22-7196 3222
Fax : +91-22-6794 2111/333
CIN L51900MH1988PLC048455
Email : info@wanbury.com
Website : www.wanbury.com

April 28, 2026

To BSE Limited PJ. Towers, Dalal Street Mumbai - 400 001. Script Code: 524212	To National Stock Exchange of India Ltd, Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051. Script Code: WANBURY
---	--

Dear Sir/Madam,

Sub.: Press release on MFDS (Ministry of Food and Drug Safety - Korea FDA) Regulatory Inspection

Pursuant to Regulation 30 (6) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, we would like to inform you as under:

Wanbury Limited, Patalganga site has completed MFDS (Ministry of Food and Drug Safety - Korea FDA) Regulatory Inspection successfully. Two inspectors inspected facility for three days i.e. from 7th April 2026 to 9th April, 2026. Inspection completed with no observation (Zero Observation) confirming cGMP compliance per international rules.

MFDS is part of PIC (Pharmaceutical inspection co-operation scheme). Company is strengthening infrastructure by adding new state of the art manufacturing block at Andhra Pradesh site for new APIs which under validation and commercialisation.

Both the API manufacturing sites are USFDA approved i.e. Patalganga and Tanuku of WL are continued to be compliant as per cGMP Rules and Regulations with Zero Observation.

Patalganga plant received zero observation from USFDA earlier. Thereafter, Tanuku plant received Zero Observation from Anvisa (Brazil FDA). Now again, Patalganga plant got Korea FDA Approval with Zero Observation.

This is for your information and record.

Thanking you.

Yours faithfully,
For Wanbury Limited

Jitendra J. Gandhi
Company Secretary

Encl.: a/a.

